KERLEDEX Drug Patent Profile

When do Kerledex patents expire, and what generic alternatives are available?

Kerledex is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in KERLEDEX is betaxolol hydrochloride; chlorthalidone. There are eleven drug master file entries for this compound. Additional details are available on the betaxolol hydrochloride; chlorthalidone profile page.

Summary for KERLEDEX

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for KERLEDEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	KERLEDEX	betaxolol hydrochloride; chlorthalidone	TABLET;ORAL	019807-001	Oct 30, 1992		DISCN	No	No
Sanofi Aventis Us	KERLEDEX	betaxolol hydrochloride; chlorthalidone	TABLET;ORAL	019807-002	Oct 30, 1992		DISCN	No	No

International Patents for KERLEDEX

See the table below for patents covering KERLEDEX around the world.

Country	Patent Number	Title	Estimated Expiration
Greece	61363	PREPARATION PROCESS OF ETHERS OF SUBSTITUTED PHENOLS
Norway	142034
Australia	1925976
New Zealand	182498	PHENOL ETHERS AND PHARMACEUTICAL COMPOSITIONS

KERLEDEX Market Analysis and Financial Projection

Last updated: February 17, 2026

What Is the Current Investment Scenario for KERLEDEX?

KERLEDEX (ketorolac tromethamine) is an injectable non-steroidal anti-inflammatory drug (NSAID) primarily used for short-term management of moderate to severe pain. Its market presence is limited by established competitors and regulatory constraints but retains niche application, particularly in postoperative pain management.

Market Reception:

• The drug faces competition from other NSAIDs and opioids, which restricts market share.
• Off-label potential exists for specific pain management settings.
• Generic versions could affect pricing strategies and margins.

Regulatory Status:

• Approved by the FDA for limited indications.
• Patent expiry or exclusivity status remains unclear, influencing investor confidence.

Financial Health:

• Limited publicly available financial data. Underlying revenues derive mainly from hospital procurement contracts.
• Minor presence in pharmaceutical pipelines for incremental formulations or indications.

What Are the Key Fundamentals for Evaluating KERLEDEX?

Regulatory Landscape

• FDA approval covers only analgesia in certain conditions.
• Broad approval is limited; off-label use is common but not FDA-supported.
• Patent expiration, if any, could lead to increased generic competition.

Market Dynamics

• The analgesic market is saturated with NSAIDs and opioids.
• Postoperative pain management is the main niche.
• Rising opioid scrutiny and preference for non-opioid analgesics may influence demand.

Competitive Environment

• Existing NSAID patents expired or near expiry.
• Several generics are available, reducing pricing power.
• Biological and biotechnological pain treatments threaten small-molecule NSAID markets.

Clinical Efficacy and Safety

• Efficacy comparable to other NSAIDs.
• Notable risks: gastrointestinal, renal, and cardiovascular adverse effects.
• Safety profile limits wider use, especially in chronic conditions.

Pricing & Reimbursement

• Reimbursement largely depends on hospital procurement policies.
• Price sensitivity due to competition.
• Potential for formulary restrictions affecting sales volume.

Development Pipeline & Future Prospects

• Limited pipeline development.
• No recent filings or new indications announced.
• Pipeline focus appears limited to incremental improvements or new formulations.

Intellectual Property

• Patent landscape indicates possible expiry or expiration of key patents.
• No recent patents filed specifically for KERLEDEX.

External Factors Influencing Investment

• Rising emphasis on opioid alternatives.
• Healthcare policies favoring non-opioid pain management.
• Price controls and hospital procurement policies impact margins.

How Does KERLEDEX Compare With Similar Drugs?

Parameter	KERLEDEX	NSAID Class (e.g., Ibuprofen, Diclofenac)	Opioids (e.g., Morphine, Fentanyl)
Approved Indications	Postoperative pain	Various pain types	Severe acute pain
Market Presence	Niche, hospital-focused	Broad, OTC and prescription	Severe, hospital, specialist use
Patent Status	Likely expired or near expiry	Most are off-patent	Patents vary; some expired
Revenue Data	Limited, mainly institutional	Hundreds of millions USD globally	Several billion USD globally
Competitive Price Point	Limited data, generally higher	Widely variable, often lower	Generally higher

What Risks Should Investors Consider?

• Competition from generics diminishes pricing.
• Regulatory restrictions limit market expansion.
• Market shift towards opioid alternatives reduces demand.
• Safety concerns restrict broader indication development.
• Lack of a significant R&D pipeline limits future growth prospects.

Final Assessment

KERLEDEX operates in a niche segment within the pain management market, with limited growth due to competition, regulatory constraints, and safety concerns. Its current valuation is restrained by modest revenue streams, and the absence of an active pipeline reduces its future potential. Investors should regard KERLEDEX as a small-scale player whose prospects depend heavily on market shifts towards non-opioid analgesics and institutional prescribing behaviors.

Key Takeaways

• KERLEDEX has a limited market presence, with revenues tied to hospital contracts.
• Patent expiry and generic competition impose downward pricing pressures.
• Regulatory and safety limitations restrict expansion.
• The opioid crisis and rising preference for alternative analgesics threaten demand.
• Lack of development activity constrains future growth potential.

FAQs

1. What is the patent status of KERLEDEX?
Patent expiry information is not publicly detailed; likely expired or nearing expiry, which invites generic competition.

2. Can KERLEDEX expand into new indications?
Limited clinical data and safety profile restrict off-label and broader use, and no new indications are under active development.

3. How does KERLEDEX compete with oral NSAIDs?
Injectable formulations target specific hospital procedures; oral NSAIDs dominate outpatient and chronic pain management, reducing KERLEDEX's market scope.

4. What is the primary risk of investing in KERLEDEX?
Market competition, generic erosion, regulatory constraints, and limited pipeline development.

5. Are there any innovative pipeline developments for KERLEDEX?
No significant or announced pipeline efforts are publicly available, indicating limited near-term growth prospects.

---

Sources: [1] FDA drug approval records.
[2] Industry reports on NSAID markets.
[3] Patent expiry and generic competition analyses.
[4] Market research firm reports on pain management.
[5] Healthcare policy documents regarding opioid alternatives.